Tuberous sclerosis complex was once thought to be a rare disease but is now known to occur in about 1 in 6000 live births, [18] making it not quite as common as neurofibromatosis type 1 (1 in 4,000 ...

Tuberous sclerosis complex is a multisystem disorder in which neurologic problems cause the greatest disability. High rates of mental retardation and autism spectrum disorders are associated with the ...

The Company plans to discontinue further clinical development of ganaxolone in TSC. Marinus Pharmaceuticals announced that its phase 3 trial of ganaxolone did not meet the primary end point for the ...

Tuberous sclerosis complex (TSC) is a rare genetic disease (approximate 1:6,000 birth incidence) with a wide variability of physical and neuropsychiatric symptoms. Patients require lifelong care from ...

Please provide your email address to receive an email when new articles are posted on . Survey responses reflected positive language and communication outcomes after cannabidiol use. Further ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...

Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that target the filamin A protein to treat central nervous system disorders. The ...

Most TSC caregivers plan to continue Epidiolex due to benefits like fewer seizures and improved cognition. New data at AES 2024 underscores Epidiolex's positive impact on TSC patients' health and well ...

Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin ...